|
产品描述： ME-401 (PWT-143, P110δ-IN-1)是一种口服的、有效的 Phosphatidylinositol 3-Kinase (PI3K) P110δ 的选择性抑制剂，在细胞分析中的IC50值为0.6 nM |
|
靶点：
P110δ(Cell-free assay):0.6 nM;PI3K |
体内研究：
ME-401 is an oral, once-daily, selective PI3Kδ inhibitor with an optimized pharmacologic profile that is in clinical development for the treatment of B-cell malignancies. ME-401 can be orally absorbed, distribute to target tissues, enter and accumulate in target cells, and bind to the target with high affinity to exert its mechanism of action. |
|
动物实验：
Animal Models: CD-1 mice, Sprague Dawley (SD) rats, Female BALB/c mice, Beagle dogs, Cynomolgus monkeys Dosages: 10 mg/kg for mice, 5 mg/kg for rats, 2 mg/kg for dogs and monkeys Administration: Oral gavage |
参考文献：
1. Ofir Moreno, et al. Clin Ther. 2018 Nov;40(11):1855-1867. 2. Ofir Moreno, Jamie Wood. Target Oncol. 2019 Oct;14(5):603-611. |
|
溶解性：
Soluble in DMSO |
|
保存条件：
-20℃ |
配置溶液浓度参考：
|
1mg |
5mg |
10mg |
| 1 mM |
1.654 ml |
8.268 ml |
16.535 ml |
| 5 mM |
0.331 ml |
1.654 ml |
3.307 ml |
| 10 mM |
0.165 ml |
0.827 ml |
1.654 ml |
| 50 mM |
0.033 ml |
0.165 ml |
0.331 ml |
|
| 注意： |
部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京